PHWR Public Health Weekly Report

Vol.17 No.32, August 14, 2024 Article TypePolicy NotesQuickStatsReview & Perspective

• Review & Perspective 2024-08-14

  2 4090 327

  2023 World Malaria Report (Status of World Malaria in 2022)

  Hyun-Il Shin, Bora Ku, Haneul Jung, So-dam Lee, Seon-Young Lee, Jung-Won Ju, Jonghee Kim, Hee-Il Lee

  Public Health Weekly Report 2024; 17(32): 1351-1377 https://doi.org/10.56786/PHWR.2024.17.32.1

  

  

  Abstract

  Full Text Cite Share

  Malaria is a disease caused by the bite of a female Anopheles spp. mosquito infected with a Plasmodium spp. parasite. Five known species of malaria infect humans: Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Among them, P. falciparum is mainly found in Africa, and P. vivax is mainly found in South-East Asia and Western Pacific regions. P. malariae and P. ovale are found in parts of Africa; P. knowlesi is found in parts of Malaysia and Indonesia; and only P. vivax is found in the Republic of Korea. According to a recently released 2023 World Malaria Report, 249 million cases of malaria in 85 countries were reported in 2022. Twenty-nine countries accounted for 95.5% of the cases, with Nigeria accounting for 26.8%, the Democratic Republic of the Congo for 12.3%, Uganda for 5.1%, and Mozambique for 4.2%. In 2022, 608,000 people died; Further, 95.9% of deaths occurred in 29 countries, with the highest number of deaths in Africa and 76.0% occurring in children under 5 years of age. No countries were certified as malaria-free in 2022.

• Policy Notes 2024-08-14

  0 62 34

  Support for Coronavirus Disease 2019 Comparator Vaccines and Research Vaccines

  Suobng Chea, Mimiso Lee, Eunyoung Jo, Joonku Park*

  Public Health Weekly Report 2024; 17(32): 1378-1390 https://doi.org/10.56786/PHWR.2024.17.32.2

  

  

  Abstract

  Full Text Cite Share

  Protecting people’s health and lives through vaccination is crucial in the event of an infectious disease such as coronavirus disease 2019 (COVID-19). Vaccines are a cost-effective way of preventing infectious diseases and their spread. The absence of domestic companies capable of rapidly developing and supplying vaccines that are effective in responding to infectious diseases can lead to supply and demand instability and disruption of smooth vaccination owing to increasing external dependence on vaccine supplies. Therefore, it is necessary to support domestic companies and research institutes that are developing vaccines, so that effective and safe vaccines can be quickly and stably supplied to prevent infectious diseases. To support domestic pharmaceutical companies and research institutes that are researching and developing COVID-19 follow-up vaccines, this article will explain the overall project to provide free comparator vaccines from clinical trials and from research studies by using the surplus of the COVID-19 vaccines purchased by the government, as well as the achievements, limitations, and improvement plans.

• QuickStats 2024-08-14

  1 66 18

  Cardio-cerebrovascular Disease Mortality Trends, 2012–2022

  Public Health Weekly Report 2024; 17(32): 1391-1392 https://doi.org/10.56786/PHWR.2024.17.32.3

  

  

  Full Text Cite Share